Drug Watch. Skin cancer.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 290
- By:
- Publication type:
- Article
Works matching IS 1082801X AND DT 2011 AND VI 46 AND IP 7
Results: 18
1
2
Policy Watch. Development of biosimilars creates challenges for FDA, manufacturers.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 288
- By:
- Publication type:
- Article
3
Meeting Coverage. 5-ARI, alpha-blocker differ in number of BPH-related complications.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 287
- Publication type:
- Article
4
Meeting Coverage. OAB agent demonstrates efficacy, tolerability in phase 3 trial.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 287
- Publication type:
- Article
5
Meeting Coverage. Generic drug trend forecasting can help MCOs rein in costs.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 286
- By:
- Publication type:
- Article
6
Meeting Coverage. CER reviews valuable, but not used to full potential.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 286
- By:
- Publication type:
- Article
7
Medication Safety and Reliability. Reports of hepatosplenic T-cell lymphoma in patients taking tumor necrosis factor blockers, azathioprine, mercaptopurine continue.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 285
- Publication type:
- Article
8
Medication Safety and Reliability. Drospirenone-containing contraceptives associated more commonly with VTE than those utilizing levonorgestrel.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 285
- Publication type:
- Article
9
Alzheimer's disease: Current treatment options and future developments.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 268
- By:
- Publication type:
- Article
10
Rivaroxaban: a novel oral factor Xa inhibitor to prevent stroke in nonvalvular atrial fibrillation.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 257
- By:
- Publication type:
- Article
11
Short-cycle prescribing puts a lid on medication waste.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 252
- By:
- Publication type:
- Article
12
Guidelines tailored to each individual's needs can improve outcomes, reduce costs.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 250
- By:
- Publication type:
- Article
13
Adoption of evidence-based therapies associated with increased survival of STEMI patients.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 250
- Publication type:
- Article
14
Low vitamin D levels may be associated with diabetes; supplementation trials needed.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 249
- By:
- Publication type:
- Article
15
Low-cost generics mixed blessing for diabetes treatment.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 249
- By:
- Publication type:
- Article
16
FDA Drug Approvals. FDA actions in brief.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 248
- Publication type:
- Article
17
FDA Drug Approvals. New indication.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 247
- Publication type:
- Article
18
FDA Drug Approvals. New molecular entity.
- Published in:
- Formulary, 2011, v. 46, n. 7, p. 247
- Publication type:
- Article